Nina Beri

1.5k total citations
14 papers, 171 citations indexed

About

Nina Beri is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Nina Beri has authored 14 papers receiving a total of 171 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Nina Beri's work include Pancreatic and Hepatic Oncology Research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer Research and Treatments (2 papers). Nina Beri is often cited by papers focused on Pancreatic and Hepatic Oncology Research (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Cancer Research and Treatments (2 papers). Nina Beri collaborates with scholars based in United States and Switzerland. Nina Beri's co-authors include Hiba AbouAssi, Eric P. Hoffman, Olga Ilkayeva, Deborah M. Muoio, Robert Stevens, Timothy R. Koves, Monica J. Hubal, Kim M. Huffman, Lori A. Bateman and William E. Kraus and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Nina Beri

14 papers receiving 165 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nina Beri United States	5	74	59	41	40	27	14	171
Matthew D. Campbell United States	7	32 0.4×	76 1.3×	16 0.4×	10 0.3×	8 0.3×	16	138
Ludmilla Kedenko Austria	7	61 0.8×	50 0.8×	8 0.2×	12 0.3×	4 0.1×	10	182
Bronwyn Neill Australia	3	51 0.7×	43 0.7×	14 0.3×	12 0.3×	2 0.1×	3	135
Renato G. Kasseroller Austria	6	52 0.7×	14 0.2×	27 0.7×	229 5.7×	11 0.4×	9	308
Yaxin Guo China	9	26 0.4×	63 1.1×	5 0.1×	24 0.6×	5 0.2×	27	235
Roberto Diaz-Marin Canada	5	39 0.5×	43 0.7×	11 0.3×	12 0.3×	3 0.1×	7	161
Mezbah U. Faruque United States	8	20 0.3×	54 0.9×	15 0.4×	22 0.6×	23 0.9×	13	196
Neng Zhou China	7	22 0.3×	98 1.7×	6 0.1×	25 0.6×	4 0.1×	10	152
Marion Combes France	3	90 1.2×	57 1.0×	7 0.2×	9 0.2×	3 0.1×	5	160

Countries citing papers authored by Nina Beri

Since Specialization

Citations

This map shows the geographic impact of Nina Beri's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nina Beri with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nina Beri more than expected).

Fields of papers citing papers by Nina Beri

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nina Beri. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nina Beri. The network helps show where Nina Beri may publish in the future.

Co-authorship network of co-authors of Nina Beri

This figure shows the co-authorship network connecting the top 25 collaborators of Nina Beri. A scholar is included among the top collaborators of Nina Beri based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nina Beri. Nina Beri is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Lynch, Ryan C., Pamela N. Münster, Gerald S. Falchook, et al.. (2023). Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors.. Journal of Clinical Oncology. 41(16_suppl). 3099–3099. 4 indexed citations

Swisher, Elizabeth M., Gerald S. Falchook, Pamela N. Münster, et al.. (2023). Abstract LB_A13: Phase 1 dose expansion results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) in platinum-resistant ovarian cancer. Molecular Cancer Therapeutics. 22(12_Supplement). LB_A13–LB_A13. 2 indexed citations

Beri, Nina. (2023). Immune Checkpoint Inhibitors in Cholangiocarcinoma. Immunotherapy. 15(7). 541–551. 1 indexed citations

Beri, Nina. (2022). Unmet Needs in the Treatment of Intrahepatic Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements. Future Oncology. 18(11). 1391–1402. 2 indexed citations

Oberstein, Paul E., Osama E. Rahma, Nina Beri, et al.. (2022). A phase 1b study evaluating IL-1β and PD-1 targeting with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).. Journal of Clinical Oncology. 40(4_suppl). 557–557. 6 indexed citations

Everett, Jessica N., Jennifer Chun, Emily Kawaler, et al.. (2022). Impact of comprehensive family history and genetic analysis in the multidisciplinary pancreatic tumor clinic setting. Cancer Medicine. 12(3). 2345–2355. 7 indexed citations

Oberstein, Paul E., Osama E. Rahma, Nina Beri, et al.. (2022). Abstract PR005: Primary results of PanCAN-SR1, a phase 1b study evaluating Gemcitabine, nab-Paclitaxel, Canakinumab, and Spartalizumab to target IL-1β and PD-1 in metastatic pancreatic cancer with correlative tissue and blood biomarker analysis. Cancer Research. 82(22_Supplement). PR005–PR005. 3 indexed citations

Oberstein, Paul E., Osama E. Rahma, Nina Beri, et al.. (2022). Initial efficacy and biomarker analysis of a phase 1b study targeting IL-1β and PD-1 with chemotherapy in metastatic pancreatic cancer (PanCAN-SR1).. Journal of Clinical Oncology. 40(16_suppl). e16287–e16287. 1 indexed citations

Lynch, Ryan C., Pamela N. Münster, Ranjana H. Advani, et al.. (2022). Phase 1 results of a phase 1/2 trial of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination, in patients with advanced solid and hematologic cancers.. Journal of Clinical Oncology. 40(16_suppl). 3084–3084. 4 indexed citations

10.

Welling, Theodore H., Nina Beri, Despina Siolas, et al.. (2020). A phase II, randomized, controlled trial of nivolumab in combination with BMS-986253 or cabiralizumab in advanced hepatocellular carcinoma (HCC) patients.. Journal of Clinical Oncology. 38(4_suppl). TPS598–TPS598. 3 indexed citations

11.

Wu, Jennifer, Lawrence P. Leichman, Hitendra Patel, et al.. (2020). A phase I/II multisite study of nivolumab and carboplatin/paclitaxel with radiation therapy (RT) in patients with locally advanced esophageal squamous cell carcinoma (ESCC).. Journal of Clinical Oncology. 38(4_suppl). 372–372. 6 indexed citations

12.

Peppercorn, Jeffrey, Kevin Houck, Nina Beri, et al.. (2015). Breast cancer screening utilization and understanding of current guidelines among rural U.S. women with private insurance. Breast Cancer Research and Treatment. 153(3). 659–667. 15 indexed citations

13.

Huffman, Kim M., Timothy R. Koves, Monica J. Hubal, et al.. (2014). Metabolite signatures of exercise training in human skeletal muscle relate to mitochondrial remodelling and cardiometabolic fitness. Diabetologia. 57(11). 2282–2295. 116 indexed citations

14.

Beri, Nina, et al.. (2013). Molecular and Clinical Associations Between Vitamin D and Chronic Lymphocytic Leukemia. Blood. 122(21). 5282–5282. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact